Cardiovascular Systems Reports Preliminary Fiscal First-Quarter Financial Results

BofA/Merrill Lynch Downgrades Cardiovascular Systems (CSII) to Underperform

BofA/Merrill Lynch downgraded Cardiovascular Systems (NASDAQ: CSII) from Buy to Underperform with a price target of $15.00.

For an analyst ratings summary and ratings history on Cardiovascular Systems click here. For more ratings news on Cardiovascular Systems click here.

Shares of Cardiovascular Systems closed at $16.63 yesterday.

Needham & Company Downgrades Cardiovascular Systems (CSII) to Buy

Needham & Company downgraded Cardiovascular Systems (NASDAQ: CSII) from Strong Buy to Buy with a price target of $18.00 (from $37.00).

Analyst Mike Matson commented, "We are downgrading CSII to Buy from Strong Buy after last night's negative preannouncement. On one hand, we see... More

Leerink Partners Downgrades Cardiovascular Systems (CSII) to Market Perform

Leerink Partners downgraded Cardiovascular Systems (NASDAQ: CSII) from Outperform to Market Perform with a price target of $17.00 (from $45.00) after the company preannounced weaker-than-expected F1Q16 sales driven by another quarter of salesforce disruption.

Analyst Danielle Antalffy commented, "Clearly the salesforce transition... More

Cardiovascular Systems (CSII) Prelim. Q1 Results Miss Expectations

Cardiovascular Systems (NASDAQ: CSII) reported preliminary results for its fiscal 2016 first quarter ended September 30, 2015.

The company expects fiscal first-quarter revenues of approximately $43.9 million, an 11 percent increase from $39.5 million in the first quarter of fiscal 2015, excluding $1.9 million from the sale of Asahi guide wires in the prior year period. The fiscal 2016 first quarter net loss is anticipated to be in the range of $(13.1) million to $(13.9) million, or $(0.41) to $(0.43) per common share, compared to a net loss of $(8.2) million, or $(0.26) per common share, in the fiscal 2015 first quarter. CSIs fiscal 2016 first-quarter results are... More